Please login to the form below
apixaban
This page shows the latest apixaban news and features for those working in and with pharma, biotech and healthcare.
UPDATED: BMS completes $13.1bn acquisition of MyoKardia
This includes the company’s oral anticoagulant Eliquis (apixaban), BMS’ second biggest product after cancer immunotherapy Opdivo (nivolumab). ... Although BMS maintained at the time that the patent for composition of matter covering apixaban in the
Latest news
-
Bristol-Myers Squibb’s revenues rise on Celgene acquisition
The positive quarterly results build on BMS’ key patent challenge victory on Wednesday for its blood thinner Eliquis (apixaban). ... While subject to appeal, at present the generic manufacturers currently involved in the case cannot launch their
-
Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls
BMS’ well-established anticoagulant Eliquis (apixaban) had another strong quarter with a 19% rise to just over $2bn, while multiple myeloma drug Empliciti (elotuzumab) grew by more than a third to
-
Vyndaqel a bright spot as Pfizer comes under pressure
ago. Meanwhile, vaccine blockbuster Prevnar also continued its slowdown, but still brought in $1.58bn in the quarter, and anticoagulant Eliquis (apixaban) continued its strong growth with a 21% gain to
-
FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis
The two companies have been actively challenging attempts by generic drugmakers to bring copycat version of Eliquis(apixaban) to market and defend the drug, which made $6.4bn for BMS last ... Last year, Aurobindo was given tentative FDA approval for
-
BMS’ Opdivo stalls in Q3, but overall figures still top expectations
Anticoagulant Eliquis (apixaban) did better than predicted with a 22% increase to $1.93bn, and there were also solid gains for arthritis and psoriasis therapy Orencia (abatacept) – up 14% to $767m –
More from news
Approximately 9 fully matching, plus 85 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2016
merger. 106. † Portola Pharmaceuticals/ BMS| Pfizer. andexanet alfa as an antidote for apixaban and other Factor Xa inhibitors (pre-reg).
-
Modern anticoagulants threaten status quo
Apixaban. Bristol-Myers Squibb and Pfizer are developing apixaban (Eliquis), which is an oral, twice-daily, selective factor Xa inhibitor. ... statistically significant reduction in mortality was also observed in apixaban recipients in this trial.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
PPD expands global product department with new therapeutic area heads
Puneet Mohan (left) comes to PPD from Bristol-Myers Squibb, where he most recently served as executive director of global clinical development and global clinical leader for Eliquis (apixaban).
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- First trial of a vaccine against Alzheimer’s launches
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Gilead to pay $745m for three oncology programmes from Arcus Biosciences
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Lucid Group: Orange the World
- First trial of a vaccine against Alzheimer’s launches
- New COVID variant causing concern
- PMEA 2021: A Celebration of Excellence in Patient Engagement
- From Academics to Entrepreneurship: How Tech is Revolutionizing the Diagnostics Landscape
- Impetus Digital wins Canada’s Most Admired Corporate Cultures Awards 2021
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Biogen’s Aduhelm unlikely to get approval in Europe
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- The pandemic preparedness paradox
- First trial of a vaccine against Alzheimer’s launches
- Good NICE news for Pfizer, but Dendreon drug rejected
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
